News

Ospemifene is developed as as vulvar and vaginal atrophy (VVA) therapy in post-menopausal women. Shionogi CEO Takashi Takenoshita said the US Food and Drug Administration has approved ospemifene

Life Technologies’ lentiviral vector technology will be leveraged in the development of next generation upcyte cells for biopharma and academic research markets. Medicyte CEO Dr. Joris Braspenning said,

The application includes safety and efficacy data of the investigational sublingual dissolvable tablet from Phase III trials including a long-term, multi-season trial. Merck Research Laboratories senior vice president,

The company has also signed the first European distribution agreements for MDS with Mokascience in France, Bucher Biotec in Switzerland and KRD Molecular Technologies in the Czech Republic,

Ekahau Wi-Fi-based temperature sensors and Ekahau Vision software will help the Hutchinson Center to monitor and report the temperatures of several hundred refrigeration units housing specimens used in

Clean air and isolator technologies will use G-CON’s mobile cleanroom PODs and Howorth’s advanced expertise in engineering to enable customers to meet safety and regulatory needs without risking

The first subject of the study is administered with defibrotide by the medical team from National University Corporation Hamamatsu University School of Medicine (HSUM), Fukushima Medical University. The

The award is intended to support the discovery of a novel series of potent compounds targeting drug abuse and alleviate pain. Dalton Medicinal Chemistry co-founder Judd Berman said,

Cegedim’s Mobile Intelligence via the cloud empowers companies with a centralized platform to consolidate interactions, improve governance and enhance strategy execution. Aptalis Pharma International Specialty Pharmaceuticals president Jean-Louis